Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) has announced a significant financing milestone, entering into a Securities Purchase Agreement with institutional accredited investors for a private placement of approximately $35.75 million. The company will sell 10,833,331 shares of its common stock at an offering price of $3.30 per share. This financing is expected to close on March 16, 2026, subject to customary closing conditions. The proceeds from this private placement will primarily support Acumen's Enhanced Brain Delivery (EBD) program, which focuses on developing novel therapeutics targeting toxic soluble amyloid beta oligomers (AβOs) for Alzheimer's disease treatment. The company aims to utilize the funds for ongoing preclinical development work to nominate a lead clinical candidate molecule and for general corporate purposes. Acumen's CEO, Daniel O'Connell, expressed confidence in the financing, stating it validates the company's portfolio and strategy. The private placement was led by existing investor RA Capital Management, with participation from other notable investors. The company has also released promising preclinical data supporting its EBD program, indicating elevated brain exposure and low risk of anemia in non-human primate studies. Acumen is targeting a lead clinical candidate IND submission for mid-2027, further enhancing its position in the Alzheimer's treatment landscape.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.